Blog · Evidence, in plain language

When your patient starts a GLP-1.

Your patients are arriving on these medicines now, prescribed for diabetes or weight, and the questions land in your room: is it safe, will it change my mood, did the news say it causes suicidal thoughts? This post sets out what the investigation actually found, and where the therapist's lane is when a patient starts one.

By Karel Winner, DNP, PMHNP-BC · Published October 4, 2026

What the investigation found

In 2023, regulators began receiving reports of suicidal thoughts in some people taking GLP-1 medicines. The FDA and European regulators opened formal reviews. In January 2026 the FDA published its conclusion: a pooled analysis of 91 placebo-controlled trials with 107,910 patients found no increased risk of suicidal thoughts or behaviors, and no increase in anxiety, depression, irritability, or psychosis. A second analysis of health records for about 2.24 million people found no increased risk of intentional self-harm. The FDA asked the makers of the weight-loss versions to remove the suicidal thoughts warning from their labels.

The published research agrees. A 2026 meta-analysis of 86 randomized trials with 133,378 participants found psychiatric problems at essentially the same rate on these medicines as off them. A Swedish national study found fewer episodes of worsening depression and anxiety during the months patients were taking a GLP-1 than during months they were not. That study compares people with themselves, which removes some distortion, and its authors still call it a signal to test rather than proof of benefit. When a patient asks whether these medicines damage mood, the accurate answer today is that the largest reviews found no increase in risk, and they are not mental health treatments either.

What belongs in the therapy room

The emotional material is real even when the medicine is safe. Appetite, weight, and eating sit close to identity, comfort, celebration, and grief, and rapid change stirs all of it. Patients may need room for reactions they did not expect, including ambivalence about succeeding. A history with food or eating deserves particular care, and a patient whose eating becomes a problem on one of these medicines should be encouraged to tell the prescriber promptly, in those words, rather than waiting for a routine appointment.

Mood reports are session material. If a patient describes a clear change in mood after starting any new medicine, the useful move is to help them report it to the prescriber accurately: what changed, when it started, and what else changed at the same time. That report is clinical information the prescriber cannot get any other way.

What is not the therapist's job

Advising on the medicine itself is outside the therapy role, and patients are better served when the boundary is clean. These medicines slow stomach emptying, which can change how some oral medicines are absorbed. Dosing questions, interaction questions, and stop-or-continue questions belong to the prescriber, and a patient who raises them in session should leave with a plan to ask the prescriber, not an answer from the therapist. The therapist who notices, asks, and routes the question is doing exactly the part of this that therapy can do well.

Sources

U.S. Food and Drug Administration, Drug Safety Communication, January 13, 2026: the FDA review of GLP-1 medicines and suicidal thoughts and behaviors, and its request to remove that warning language from the weight-loss labels. Medscape's report of the FDA announcement.

Han and colleagues, Diabetes, Obesity and Metabolism (2026): a systematic review and meta-analysis of 86 randomized trials with 133,378 participants, on GLP-1 medicines and psychiatric disorders. PubMed record.

Swedish national cohort study, The Lancet Psychiatry (2026): GLP-1 use and worsening mental illness in people with depression and anxiety. The Lancet Psychiatry.

Systematic review of psychiatric safety, Cureus (2026): 11 studies covering more than 4.9 million patients. PubMed record.

If a patient is having thoughts of harming themselves, the crisis standard applies whatever the cause: call or text 988, text HOME to 741741 for Crisis Text Line, or see the crisis page.